Abiopharma

🔍 MORTON DAVID H JR (Executive)

Company: Intapp, Inc. (INTA)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Sold 18,800 shares of Common Stock at $40.6969 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 85,590.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 1,200 shares of Common Stock at $41.0017 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 84,390.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The sale of shares of common stock of Intapp, Inc. was executed pursuant to a 10b5-1 plan put in place by the Reporting Person on August 14, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from (a) with respect to the weighted average price of $40.6969: $40.00 to $40.99, inclusive, and (b) with respect to the weighted average price of $41.0017: $41.00 to $41.01, inclusive. The reporting person undertakes to provide to Intapp, Inc., any security holder of Intapp, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
• F3: Includes 351 shares purchased at a price of $19.63 pursuant to the Intapp, Inc. 2021 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of December 1, 2025, through May 31, 2026. In accordance with the ESPP, these shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of Issuer common stock on May 31, 2026.